MedTrace Logo

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

NCT06859775 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-06

No results posted yet for this study

Summary

This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.

Conditions

  • Recurrent or Metastatic Cervical Cancer

Interventions

DRUG

SHR-A1811

SHR-A1811 injection.

DRUG

Adebelimab injection

Adebelimab injection.

DRUG

Bevacizumab injection

Bevacizumab injection.

DRUG

SHR-8068

SHR-8068 injection.

DRUG

Cisplatin injection

Cisplatin injection.

DRUG

Carboplatin injection

Carboplatin injection.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-25
Primary Completion
2026-10-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06859775 on ClinicalTrials.gov